This article is mentioned in:

Introduction

In lung cancer patients, metastases to the peritoneum as well as to the spinal space are rare (1–10). Carcinomatous meningitis, which attracts increasing attention as a recurrence site in patients who received treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) (2–8), is a devastating event occurring in lung cancer patients (9–10) for which currently available treatment options are limited and the prognosis remains poor (1,9–10). This is the presentation of a case of peritoneal and meningeal relapse from lung adenocarcinoma following response to gefitinib therapy. This case report conformed to the Ethical Guidelines for Clinical Studies issued by the Ministry of Health, Labor and Welfare of Japan. Comprehensive informed consent with regard to clinical significance was obtained from the patient.

Case report

A 72-year-old woman was admitted to our hospital complaining of a persistent cough that had appeared 2 months before. The patient had never been a smoker and had no other significant medical history. Chest radiograph at admission revealed a loculated pleural effusion in the left hemithorax (Fig. 1). The cytological diagnosis of the pleural fluid specimen was adenocarcinoma. Since there were no distant metastases or tumorous lesions in other organs where adenocarcinoma may develop, the diagnosis was lung adenocarcinoma.

Figure 1. Chest radiograph at admission revealed a loculated pleural effusion in the left hemithorax.

The patient received 4 courses of cisplatin-based chemotherapy and the response was evaluated as partial. Two months following the completion of chemotherapy, the patient developed dyspnea on exertion due to reaccumulation of left pleural fluid and the cytological pleural fluid specimens showed an EGFR mutation (L858R point mutation in exon 21). Therefore, the patient was started on 250 mg/day gefitinib therapy and the dyspnea disappeared within 2 weeks. A grade 1 (National Cancer Institute common toxicity criteria version 2.0) skin rash was observed, but it was tolerable. Eight months after the initiation of gefitinib, the patient developed abdominal distension, gait disturbance and visual disorder of the right eye. Massive ascites were revealed by abdominal computed tomography (CT) scan (Fig. 2). Positive lymph nodes were identified around the abdominal aorta, although no metastatic lesions were detected in the abdominal organs on the CT scan. Adenocarcinoma cells were detected in the ascitic and pleural fluids. Due to the deterioration of the performance status (PS 4), the patient received supportive care and succumbed to the disease 2 months following peritoneal and meningeal relapse.

Figure 2. Abdominal computed tomography (CT) scan at the time of recurrence revealed massive ascites.

Discussion

Carcinomatous meningitis occurs in ∼5% of cancer patients (11) and is considered to be an oncological emergency requiring immediate treatment (12). Treatment options include whole-brain irradiation, systemic chemotherapy and intrathecal chemotherapy, such as methotrexate (12). However, despite these treatments, focal neurological dysfunctions do not improve in the majority of cases (13) and the prognosis remains poor, with a median survival of 2–3 months (12). Recently, the benefits of EGFR-TKIs in the treatment of carcinomatous meningitis in patients with non-small-cell lung cancer (NSCLC) have attracted attention, although all studies were case reports or case series (2–8). Furthermore, there is a high incidence of disease recurrence in the brain and leptomeninges in NSCLC patients after response to gefitinib treatment (14).

Metastatic involvement of the peritoneum is not a rare autopsy finding (15–17). Based on previous studies, the incidence of carcinomatous peritonitis is 2.7–16% in lung cancer patients (15–17). However, carcinomatous peritonitis from lung cancer is infrequently encountered and clinical reports on this type of distant metastasis are rare. We previously reported that 12 (1.2%) out of 1,041 patients with lung cancer developed carcinomatous peritonitis (1). The incidence of peritoneal carcinomatosis was high among patients with adenocarcinoma. The median survival time from the diagnosis of carcinomatous peritonitis was 2 months (1). Our previous and present findings, taken together, suggest that ascites accompanying metastasis to abdominal organs and pleural seeding in a patient with known lung cancer should be regarded as metastasis (1).

A previous study by Su et al (18) also reported clinicopathological findings in 30 lung cancer patients with carcinomatous peritonitis. According to their findings, the most frequent abdominal symptom of carcinomatous peritonitis was abdominal distension and the most common histological type of lung cancer was adenocarcinoma. Eighty percent of the patients developed malignant pleural effusions prior to the diagnosis of carcinomatous peritonitis. Notably, 4 patients with lung adenocarcinoma and carcinomatous peritonitis were treated with gefitinib. Two of them, who responded to therapy, demonstrated improved abdominal conditions with gradually diminishing ascites and survived for 203 and 343 days, in marked contrast to the previously reported poor median survival of 15 days (18). There is also another previous report of a patient with lung adenocarcinoma and carcinomatous peritonitis who responded to gefitinib therapy (19). It should be noted that these patients were successfully treated for carcinomatous peritonitis by gefitinib (18,19). However, there were also patients with peritoneal recurrence following successful treatment with gefitinib, such as the present case report. The existence of two different responses (good response of peritonitis to gefitinib and peritoneal recurrence following a good response to gefitinib), seems to be similar to the observations made in lung cancer patients with carcinomatous meningitis.

Irrespective of the peritoneal or subarachnoid space, there may be other uncommon recurrence sites in lung cancer patients. This suggests that such an unusual recurrence may be associated with insufficient concentration of gefitinib at these sites. Although it is rarely encountered, clinicians should remain vigilant for this type of recurrence in lung cancer patients, even following the successful treatment with EFFR-TKIs.

References